BBA
PRAX icon

Baker Bros. Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Baker Bros. Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565M Buy
1,753,198
+626,710
+56% +$194M 3.24% 11
2025
Q4 		$332M Buy
1,126,488
+437,000
+63% +$81.4M 1.94% 12
2025
Q3 		$36.5M Hold
689,488
– – 0.26% 36
2025
Q2 		$29M Buy
689,488
+357,955
+108% +$13.6M 0.28% 32
2025
Q1 		$12.6M Hold
331,533
– – 0.14% 41
2024
Q4 		$25.5M Buy
331,533
+8,428
+3% +$610K 0.27% 40
2024
Q3 		$18.6M Buy
323,105
+191,572
+146% +$10.3M 0.19% 44
2024
Q2 		$5.44M Hold
131,533
– – 0.07% 62
2024
Q1 		$8.03M Hold
131,533
– – 0.1% 55
2023
Q4 		$2.93M Buy
131,533
+6,205
+5% +$112K 0.03% 68
2023
Q3 		$3.21M Hold
125,328
– – 0.02% 74
2023
Q2 		$2.16M Hold
125,328
– – 0.01% 93
2023
Q1 		$1.52M Buy
125,328
+3,307
+3% +$140K 0.01% 95
2022
Q4 		$4.36M Buy
+122,021
New +$3.81M 0.03% 80

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's PRAX Position: Q1 2026 in Review

Baker Bros. Advisors increased its Praxis Precision Medicines (PRAX) stake by 56% in Q1 2026, buying an estimated $194M and bringing the position to 1,753,198 shares worth $565M. The position accounts for 3.24% of the portfolio, ranked #11.

Baker Bros. Advisors first reported a position in PRAX in Q4 2022 and has held it in 14 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Baker Bros. Advisors held 1,753,198 shares of Praxis Precision Medicines worth $565M as of Q1 2026.
  • Baker Bros. Advisors bought 626,710 Praxis Precision Medicines shares in Q1 2026, an estimated $194M.
  • Praxis Precision Medicines made up 3.24% of Baker Bros. Advisors's portfolio in Q1 2026, its #11 holding.
  • Baker Bros. Advisors first reported a position in Praxis Precision Medicines in Q4 2022 and has held it in 14 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.